<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">To address the effects of COVID-19 and to simultaneously ensure the continuity of development of non-COVID treatments, regulators have demonstrated significant regulatory agility while maintaining high standards of quality, tolerability, and effectiveness.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref>
</p>
